Praxis Precision Medicines’ (PRAX) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $150.00 target price on the stock. A number of other research firms have also commented on PRAX. Oppenheimer lifted their price […]
Needham & Company LLC reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a $150.00 target price on the stock. A number of other research firms have also commented on PRAX. Oppenheimer lifted their price […]
